Diagnosis and Management of Acute Myelopathies

BACKGROUND:Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Neurologist (Baltimore, Md.) Md.), 2005-01, Vol.11 (1), p.2-18
Hauptverfasser: Kaplin, Adam I., Krishnan, Chitra, Deshpande, Deepa M., Pardo, Carlos A., Kerr, Douglas A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 18
container_issue 1
container_start_page 2
container_title The Neurologist (Baltimore, Md.)
container_volume 11
creator Kaplin, Adam I.
Krishnan, Chitra
Deshpande, Deepa M.
Pardo, Carlos A.
Kerr, Douglas A.
description BACKGROUND:Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations, and autonomic dysfunction. TM may exist as part of a multifocal CNS disease (eg, MS), multisystemic disease (eg, systemic lupus erythematosus), or as an isolated, idiopathic entity. REVIEW SUMMARY:In this article, we summarize recent classification and diagnostic schemes, which provide a framework for the diagnosis and management of patients with acute myelopathy. Additionally, we review the state of current knowledge about the epidemiology, natural history, immunopathogenesis, and treatment strategies for patients with TM. CONCLUSIONS:Our understanding of the classification, diagnosis, pathogenesis, and treatment of TM has recently begun to expand dramatically. With more rigorous criteria applied to distinguish acute myelopathies and with an emerging understanding of immunopathogenic events that underlie TM, it may now be possible to effectively initiate treatments in many of these disorders. Through the investigation of TM, we are also gaining a broader appreciation of the mechanisms that lead to autoimmune neurologic diseases in general.
doi_str_mv 10.1097/01.nrl.0000149975.39201.0b
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67344423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67344423</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1842-8c57748d5b23077482d6471a9e89e5381d7d7c23e6104fd2ac5545966b8991fc3</originalsourceid><addsrcrecordid>eNo1kE1Lw0AQhhdRbK3-BQkevCXu7Gf2WOontHjRc9gkkza6-TCbUPrvXWmdywwvDwPvQ8gd0ASo0Q8UknZwCQ0DwhgtE25YCGl-RuaMc4iZ4vqczIFqEWvDYUauvP8KuFFMXJIZSMVBCTonyWNtt23nax_Ztow2trVbbLAdo66KlsU0YrQ5oOt6O-5q9NfkorLO481pL8jn89PH6jVev7-8rZbruIdUsDgtpNYiLWXOOP27WKmEBmswNSh5CqUudcE4KqCiKpktpBTSKJWnxkBV8AW5P_7th-5nQj9mTe0LdM622E0-U5oLIULXBbk9gVPeYJn1Q93Y4ZD9NwyAOAL7zo04-G837XHIdmjduMuCEqZTw2NGqaQQjMZ_Whn_BYFHYlc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67344423</pqid></control><display><type>article</type><title>Diagnosis and Management of Acute Myelopathies</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Kaplin, Adam I. ; Krishnan, Chitra ; Deshpande, Deepa M. ; Pardo, Carlos A. ; Kerr, Douglas A.</creator><creatorcontrib>Kaplin, Adam I. ; Krishnan, Chitra ; Deshpande, Deepa M. ; Pardo, Carlos A. ; Kerr, Douglas A.</creatorcontrib><description>BACKGROUND:Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations, and autonomic dysfunction. TM may exist as part of a multifocal CNS disease (eg, MS), multisystemic disease (eg, systemic lupus erythematosus), or as an isolated, idiopathic entity. REVIEW SUMMARY:In this article, we summarize recent classification and diagnostic schemes, which provide a framework for the diagnosis and management of patients with acute myelopathy. Additionally, we review the state of current knowledge about the epidemiology, natural history, immunopathogenesis, and treatment strategies for patients with TM. CONCLUSIONS:Our understanding of the classification, diagnosis, pathogenesis, and treatment of TM has recently begun to expand dramatically. With more rigorous criteria applied to distinguish acute myelopathies and with an emerging understanding of immunopathogenic events that underlie TM, it may now be possible to effectively initiate treatments in many of these disorders. Through the investigation of TM, we are also gaining a broader appreciation of the mechanisms that lead to autoimmune neurologic diseases in general.</description><identifier>ISSN: 1074-7931</identifier><identifier>EISSN: 2331-2637</identifier><identifier>DOI: 10.1097/01.nrl.0000149975.39201.0b</identifier><identifier>PMID: 15631640</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>Acute Disease ; Decision Trees ; Diagnosis, Differential ; Humans ; Myelitis, Transverse - diagnosis ; Myelitis, Transverse - immunology ; Myelitis, Transverse - therapy ; Prognosis ; Recurrence ; Spinal Cord - immunology ; Spinal Cord - pathology</subject><ispartof>The Neurologist (Baltimore, Md.), 2005-01, Vol.11 (1), p.2-18</ispartof><rights>2005 Lippincott Williams &amp; Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15631640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaplin, Adam I.</creatorcontrib><creatorcontrib>Krishnan, Chitra</creatorcontrib><creatorcontrib>Deshpande, Deepa M.</creatorcontrib><creatorcontrib>Pardo, Carlos A.</creatorcontrib><creatorcontrib>Kerr, Douglas A.</creatorcontrib><title>Diagnosis and Management of Acute Myelopathies</title><title>The Neurologist (Baltimore, Md.)</title><addtitle>Neurologist</addtitle><description>BACKGROUND:Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations, and autonomic dysfunction. TM may exist as part of a multifocal CNS disease (eg, MS), multisystemic disease (eg, systemic lupus erythematosus), or as an isolated, idiopathic entity. REVIEW SUMMARY:In this article, we summarize recent classification and diagnostic schemes, which provide a framework for the diagnosis and management of patients with acute myelopathy. Additionally, we review the state of current knowledge about the epidemiology, natural history, immunopathogenesis, and treatment strategies for patients with TM. CONCLUSIONS:Our understanding of the classification, diagnosis, pathogenesis, and treatment of TM has recently begun to expand dramatically. With more rigorous criteria applied to distinguish acute myelopathies and with an emerging understanding of immunopathogenic events that underlie TM, it may now be possible to effectively initiate treatments in many of these disorders. Through the investigation of TM, we are also gaining a broader appreciation of the mechanisms that lead to autoimmune neurologic diseases in general.</description><subject>Acute Disease</subject><subject>Decision Trees</subject><subject>Diagnosis, Differential</subject><subject>Humans</subject><subject>Myelitis, Transverse - diagnosis</subject><subject>Myelitis, Transverse - immunology</subject><subject>Myelitis, Transverse - therapy</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Spinal Cord - immunology</subject><subject>Spinal Cord - pathology</subject><issn>1074-7931</issn><issn>2331-2637</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1Lw0AQhhdRbK3-BQkevCXu7Gf2WOontHjRc9gkkza6-TCbUPrvXWmdywwvDwPvQ8gd0ASo0Q8UknZwCQ0DwhgtE25YCGl-RuaMc4iZ4vqczIFqEWvDYUauvP8KuFFMXJIZSMVBCTonyWNtt23nax_Ztow2trVbbLAdo66KlsU0YrQ5oOt6O-5q9NfkorLO481pL8jn89PH6jVev7-8rZbruIdUsDgtpNYiLWXOOP27WKmEBmswNSh5CqUudcE4KqCiKpktpBTSKJWnxkBV8AW5P_7th-5nQj9mTe0LdM622E0-U5oLIULXBbk9gVPeYJn1Q93Y4ZD9NwyAOAL7zo04-G837XHIdmjduMuCEqZTw2NGqaQQjMZ_Whn_BYFHYlc</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Kaplin, Adam I.</creator><creator>Krishnan, Chitra</creator><creator>Deshpande, Deepa M.</creator><creator>Pardo, Carlos A.</creator><creator>Kerr, Douglas A.</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200501</creationdate><title>Diagnosis and Management of Acute Myelopathies</title><author>Kaplin, Adam I. ; Krishnan, Chitra ; Deshpande, Deepa M. ; Pardo, Carlos A. ; Kerr, Douglas A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1842-8c57748d5b23077482d6471a9e89e5381d7d7c23e6104fd2ac5545966b8991fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acute Disease</topic><topic>Decision Trees</topic><topic>Diagnosis, Differential</topic><topic>Humans</topic><topic>Myelitis, Transverse - diagnosis</topic><topic>Myelitis, Transverse - immunology</topic><topic>Myelitis, Transverse - therapy</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Spinal Cord - immunology</topic><topic>Spinal Cord - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaplin, Adam I.</creatorcontrib><creatorcontrib>Krishnan, Chitra</creatorcontrib><creatorcontrib>Deshpande, Deepa M.</creatorcontrib><creatorcontrib>Pardo, Carlos A.</creatorcontrib><creatorcontrib>Kerr, Douglas A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Neurologist (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaplin, Adam I.</au><au>Krishnan, Chitra</au><au>Deshpande, Deepa M.</au><au>Pardo, Carlos A.</au><au>Kerr, Douglas A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and Management of Acute Myelopathies</atitle><jtitle>The Neurologist (Baltimore, Md.)</jtitle><addtitle>Neurologist</addtitle><date>2005-01</date><risdate>2005</risdate><volume>11</volume><issue>1</issue><spage>2</spage><epage>18</epage><pages>2-18</pages><issn>1074-7931</issn><eissn>2331-2637</eissn><abstract>BACKGROUND:Acute myelopathies represent a heterogeneous group of disorders with distinct etiologies, clinical and radiologic features, and prognoses. Transverse myelitis (TM) is a prototype member of this group in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations, and autonomic dysfunction. TM may exist as part of a multifocal CNS disease (eg, MS), multisystemic disease (eg, systemic lupus erythematosus), or as an isolated, idiopathic entity. REVIEW SUMMARY:In this article, we summarize recent classification and diagnostic schemes, which provide a framework for the diagnosis and management of patients with acute myelopathy. Additionally, we review the state of current knowledge about the epidemiology, natural history, immunopathogenesis, and treatment strategies for patients with TM. CONCLUSIONS:Our understanding of the classification, diagnosis, pathogenesis, and treatment of TM has recently begun to expand dramatically. With more rigorous criteria applied to distinguish acute myelopathies and with an emerging understanding of immunopathogenic events that underlie TM, it may now be possible to effectively initiate treatments in many of these disorders. Through the investigation of TM, we are also gaining a broader appreciation of the mechanisms that lead to autoimmune neurologic diseases in general.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>15631640</pmid><doi>10.1097/01.nrl.0000149975.39201.0b</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1074-7931
ispartof The Neurologist (Baltimore, Md.), 2005-01, Vol.11 (1), p.2-18
issn 1074-7931
2331-2637
language eng
recordid cdi_proquest_miscellaneous_67344423
source MEDLINE; Journals@Ovid Complete
subjects Acute Disease
Decision Trees
Diagnosis, Differential
Humans
Myelitis, Transverse - diagnosis
Myelitis, Transverse - immunology
Myelitis, Transverse - therapy
Prognosis
Recurrence
Spinal Cord - immunology
Spinal Cord - pathology
title Diagnosis and Management of Acute Myelopathies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20Management%20of%20Acute%20Myelopathies&rft.jtitle=The%20Neurologist%20(Baltimore,%20Md.)&rft.au=Kaplin,%20Adam%20I.&rft.date=2005-01&rft.volume=11&rft.issue=1&rft.spage=2&rft.epage=18&rft.pages=2-18&rft.issn=1074-7931&rft.eissn=2331-2637&rft_id=info:doi/10.1097/01.nrl.0000149975.39201.0b&rft_dat=%3Cproquest_pubme%3E67344423%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67344423&rft_id=info:pmid/15631640&rfr_iscdi=true